In a big shift of focus, the personal genomics company 23andMe recently announced the creation of a new therapeutics group with the intention of developing new therapies for both common and rare diseases.
The Precision Medicine Initiative
February 17, 2015 | by
In his State of the Union address last month, President Obama announced the Precision Medicine Initiative, a bold new research effort to revolutionize how we improve health and treat disease.
NIH, Industry and Non-profits Partner to Accelerate Identification of Disease Targets
March 4, 2014 | by
Last month, the National Institutes of Health, 10 biopharmaceutical companies and several nonprofit organizations launched an unprecedented partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.
2012: Banner Year for New Drugs
February 12, 2013 | by
Fueled by new cancer therapeutics, last year the annual new molecular and biological entity approval count from the U.S. Food and Drug Administration (FDA) saw its highest year since 1997. One-third of the novel products approved by the FDA’s Center for Drug Evaluation and Research (CDER) are used to treat cancers of the blood, breast, colon, prostate, skin and thyroid.
NIH Common Fund Announces New Programs
July 2, 2012 | by
New programs exploring novel approaches to cell-to-cell communication and understanding undiagnosed diseases, which represent challenges or scientific opportunities for a wide array of health research, are the latest priorities for the National Institutes of Health Common Fund. The funding was announced today by NIH Director Francis S. Collins, M.D., Ph.D., after he received broad community input and recommendations from institute and center directors at NIH. The Common Fund targets strategic investments that have the potential for rapid and significant impact. The programs are scheduled to begin during fiscal year 2013.
